** Shares of drugmaker Amgen AMGN.O fall 5.8% to $272.64
** Company says people started on a low dose of its experimental obesity drug, MariTide, achieved weight loss comparable to those on higher doses, while experiencing milder side effects in a mid-stage clinical trial
** Company adds that vomiting was reported in nearly 90% of patients started at the highest tested dose, compared with 50% of patients who ramped up to a full dose in one step and 22% of those brought to their target dose over eight weeks
** In late-stage trials, Novo Nordisk's NOVOb.CO GLP-1 obesity drug Wegovy had a vomiting rate of 24%, while Eli Lilly's LLY.N Zepbound had a rate of 13%
** Amgen says trial discontinuation rates due to gastrointestinal issues of up to 7.8% were lower for groups treated with escalating doses
** Amgen plans to initiate additional late-stage studies this year to test MariTide in patients with various serious health conditions
** Including session moves, stock up 5.2% YTD
(Reporting by Sneha S K)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.